Axatilimab + CAR-T for High-Risk Lymphoma

Part of paid clinical trials in Atlanta, Georgia.

Sponsor
Northside Hospital, Inc.
Study ID
NCT07638982
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Diffuse Large B Cell Lymphoma (DLBCL)
  • Follicular Grade 3 Lymphoma
  • High-Grade B-Cell Lymphoma, Nos
  • High-grade B-cell Lymphoma (HGBCL)
  • PMBCL
  • Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

Eligibility Criteria

Sex
ALL
Age
8 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Axatilimab — DRUG
    Dose Level -1: 0.1mg/kg Dose Level +1: 0.3mg/kg Dose Level +2: 1mg/kg Dose Level +3: 3mg/kg

Study Details

Axatilimab + CAR-T in High-Risk Lymphoma

Key Dates

Start date
Oct 31, 2026
Status verified
Jun 2026
Primary completion
Dec 31, 2028
Completion
Dec 31, 2029

Study Design

Enrollment
29 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Axatilimab + Commercial CAR T cell therapy

Primary Outcome Measure

Determine the recommended Phase 2 dose (RP2D) of axatilimab [ Time Frame: 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Northside HospitalAtlantaGeorgia30342
Caitlin Guzowski, MBA, MHA, CCRC
[email protected]
404-851-8523

Find similar trials in Atlanta, GA

By research site
Northside Hospital· Atlanta, GA

Related Studies